Compare SHMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | ENTX |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | Germany | Israel |
| Employees | 734 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.8M | 147.4M |
| IPO Year | N/A | 2015 |
| Metric | SHMD | ENTX |
|---|---|---|
| Price | $4.95 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 401.5K | ★ 3.7M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $0.91 |
| 52 Week High | $10.65 | $4.20 |
| Indicator | SHMD | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 62.47 |
| Support Level | $4.78 | $1.26 |
| Resistance Level | $5.47 | $3.22 |
| Average True Range (ATR) | 0.36 | 0.38 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 72.53 | 42.77 |
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.